ZymeworksNYSE: ZYME

VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ZW171, a novel 2+1 T-cell targeting bispecific antibody for mesothelin (MSLN)-expressing cancers.

VANCOUVER, British Columbia, June 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has accepted the BLA for zanidatamab for second-line treatment of HER2-positive BTC. Under the terms of Zymeworks' Asia Pacific license and collaboration agreement with BeiGene for the development and commercialization of zanidatamab, Zymeworks is entitled to receive an $8 million milestone payment. Zymeworks also remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales in the Asia Pacific region.

NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Zymeworks Inc. ("Zymeworks") (NASDAQ:ZYME) concerning possible violations of federal securities laws. Zymeworks disclosed, on April 1, 2024, that it had removed Christopher Astle ("Astle") from the positions of Senior Vice President ("SVP") and Chief Financial Officer ("CFO"), effective immediately.

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:

Levi & Korsinsky has started investigating Zymeworks Inc. for potential breaches of federal securities laws after the company announced the removal of Christopher Astle as Senior Vice President and Chief Financial Officer on April 1, 2024.

Levi & Korsinsky has started investigating Zymeworks Inc. for potential breaches of federal securities laws following the removal of Christopher Astle as Senior Vice President and Chief Financial Officer on April 1, 2024.

Levi & Korsinsky has started investigating Zymeworks Inc. for potential breaches of federal securities laws following the removal of Christopher Astle as Senior Vice President and Chief Financial Officer.

Zymeworks Inc. (NASDAQ: ZYME) held its Q1 2024 Earnings Call on May 2, 2024, with participants including Shrinal Inamdar, Ken Galbraith, and Paul Moore. Conference Call attendees included Stephen Willey, Ashiq Mubarack, Ivy Wang, Brian Cheng, and Jon Miller. The conference operator thanked everyone for joining the call.

Zymeworks Inc. (ZYME) reported a quarterly loss of $0.42 per share, which was higher than the expected loss of $0.31 per share according to the Zacks Consensus Estimate. This is an increase from the loss of $0.37 per share reported in the same quarter last year.